Publications

Project

Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control

Carter BL, Coffey CS, Ardery G, Uribe L, Ecklund D, James P, Egan B, Vader Weg M, Chrischilles E, Vaught T.

Circulation, Cardiovascular Quality and Outcomes. 2015 March 24; 8 (3) 235-43.

PubMed:

PMC4618490

Outpatient blood pressure monitoring using bi-directional text messaging

Anthony CA, Polgreen LA, Chounramany J, Foster ED, Goerdt CJ, Miller ML, Suneja M, Segre AM, Carter BL, Polgreen PM

Journal of the American Society of Hypertension. 2015 January 21; 9 (5) 375-381.

PubMed:

25771023

You May Have Worked on More Adaptive Designs than You Think

Coffey CS

Stroke. 2015 January 8; 46 (2) e26-28.

PubMed:

PMC4308449

Adaptive Designs for Comparative Effectiveness Research Trials

Kairalla JA, Coffey CS, Thomann MA, Shorr RI, and Muller KE

Clinical Research and Regulatory Affairs. 2014 November 13; 32 (1) 36-44.

PubMed:

PMC5074387

Adaptive Design: Results of 2012 Survey on Perception and Use

Morgan C, Huyck S, Jenkins M, Chen L, Bedding A, Coffey C, Gaydos B, and Wathen J

Therapeutic Innovation & Regulatory Science. 2014; 48 (4) 473-481.

PubMed:

30235570

Physician-Pharmacist Collaborative Management of Asthma in Primary Care

Gums TH, Carter BL, Milavetz G, Buys L, Rosenkrans K, Uribe L, Coffey C, MacLaughlin EJ, Young RB, Ables AZ, Patel-Shori N, and Wisniewski A

Pharmacotherapy. 2014; 34 (10) 1033-1042.

PubMed:

PMC4188693

Predictors of Mortality in Patients with Lacunar Stroke in the Secondary Prevention of Small Subcortical Strokes Trial

Sharma M, Pearce LA, Benavente OR, Anderson DC, Connolly SJ, Palacio S, Coffey CS, and Hart RG

Stroke. 2014; 45 (10) 2989-2994.

PubMed:

PMC4175186

C-Reactive Protein as a Prognostic Marker After Lacunar Stroke: Levels of Inflammatory Markers in the Treatment of Stroke Study

Elkind MS, Luna JM, McClure LA, Zhang Y, Coffey CS, Roldan A, Del Brutto O, Pretell EJ, Pettigrew LC, Meyer BC, Tapia J, White C, and Benavente OR on behalf of the LIMITS Investigators

Stroke. 2014 February 12; 45 (3) 707-716.

PubMed:

PMC4114338

Designing Clinical Trials for Dystonia

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JLP, Yeatts SD, and Jinnah HA

Neurotherapeutics. 2014 January; 11 (1) 117-127.

PubMed:

PMC3899487

Association of Cerebrospinal Fluid Aβ1-42, t-tau, p-tau181, and α-synuclein Levels with Clinical Features of Early Drug Naïve Parkinson’s Disease Patients

Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligorska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM and the Parkinson’s Progression Marker Initiative Investigators

Archives of Neurology. 2013 October; 70 (10) 1277-1287.

PubMed:

PMC4034348

You are here

Publications